Sanofi Pasteur (Canada) opens C$101 million vaccine R&D facility in Toronto

Sanofi Pasteur Limited (Canada) said it opened a C$101 million dollar vaccine research and development facility at Sanofi Pasteur’s Connaught Campus in north Toronto. This new facility “establishes the Connaught Campus as the North American Centre of Excellence in analytical and bioprocessing R&D for Sanofi Pasteur globally (and) solidifies the Toronto site as a national strategic asset for the research, development and manufacturing of vaccines that protect public health – in Canada and around the world.”  The province of Ontario contributed C$13.9 million to the project through the Biopharmaceutical Investment Program, part of the Next Generation of Jobs Fund. The new R&D facility, known internally as “Building 95“, “will help the company retain over 300 highly-skilled vaccine research positions and bring many of the company’s accomplished scientists and state-of-the-art technologies under one roof.” Sanofi noted that the site “manufactures many vaccines vital to public health with 94% of its vaccine production being delivered to over 90 countries around the world.